Elevance Health shares slid 7.5% in pre-open trading to $394.75 following the company's latest quarterly report, where it exceeded top-line and bottom-line estimates but also disclosed a marked squeeze on profitability.
The insurer recorded adjusted earnings per share of $7.45, topping the consensus view of $6.21 by $1.24. Revenue totaled $49.8 billion, outpacing the estimated $48.63 billion. Despite those beats, traders zeroed in on deteriorating margins rather than the upside in headline figures.
Margin deterioration at the center of the move
Operating margin narrowed to 3.5% from 4.9% in the year-ago quarter. On an adjusted basis, operating margin fell to 3.6% from 5.0% year over year. Management flagged a worsening benefit expense ratio, which the company attributed to ongoing Medicaid cost pressures and lower enrollment trends spanning the Commercial Individual and Medicaid businesses. Those dynamics undermined the profitability picture even as reported dollars and earnings beat forecasts.
Outlook and consensus
For the full year, Elevance now expects adjusted earnings of at least $27 per share, a modest increase from the prior outlook of at least $26.75 per share. Wall Street analysts were looking for an average of $26.86 per share for annual adjusted profit, leaving the raised guidance only slightly above consensus.
Analyst sentiment and market context
The pre-market decline occurred against a backdrop of generally constructive analyst activity. Several firms - including Truist, TD Cowen, Wells Fargo, Mizuho, and Bernstein - had lifted their price targets for ELV in the days before the report, which likely heightened expectations for the print. At the same time, broader U.S. equities were modestly higher, with the S&P 500 up 0.2% and the Nasdaq up 0.4%, indicating the selling pressure on Elevance was company-specific rather than driven by a broader market pullback.
The combination of a clear earnings beat, revenue outperformance, a small upward tweak to guidance, and a stock that had already rallied heading into the quarterly release appears to have created the conditions for the sharp pre-market pullback. Market participants signaled they want firmer evidence that Medicaid-related margins have stabilized before rewarding further multiple expansion.
Bottom line
Elevance delivered stronger-than-expected revenue and adjusted EPS, but the contraction in operating and adjusted operating margins and a worsening benefit expense ratio tied to Medicaid cost pressures and declining enrollment across key segments drove the stock lower in pre-market trading despite modestly positive market and analyst conditions.